Related Experiment Videos
[Clinical experience with BRL 25000 (clavulanic acid-amoxicillin) granules in pediatric infections]
The Japanese Journal of Antibiotics
|February 1, 1985
Abstract:
BRL 25000 granules containing amoxicillin 2 parts and clavulanic acid 1 part, were administered to 14 patients with pediatric infections. The overall efficacy rate was 71.4% (10/14). An adverse reaction was observed in 1 case with diarrhea, but there were no other side effects or abnormal laboratory findings noted.
Insights
Amoxicillin and clavulanic acid granules effectively treated pediatric infections in 71.4% of patients. While one case of diarrhea occurred, the treatment demonstrated a good safety profile with no other adverse events.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pediatrics
Context:
- Pediatric infections pose a significant health challenge.
- Amoxicillin-clavulanate is a widely used antibiotic combination.
- Evaluating new formulations is crucial for optimizing treatment.
Purpose:
- To assess the efficacy and safety of BRL 25000 granules in treating pediatric infections.
- To determine the clinical outcomes and adverse effects of amoxicillin-clavulanate granules.
Summary:
- BRL 25000, a combination of amoxicillin and clavulanic acid (2:1 ratio), was administered to 14 pediatric patients.
- An overall efficacy rate of 71.4% (10 out of 14 patients) was achieved.
- One patient experienced diarrhea; no other adverse reactions or abnormal laboratory findings were reported.
Impact:
- BRL 25000 granules demonstrate favorable efficacy and safety for pediatric infections.
- This formulation offers a potential treatment option for common childhood bacterial infections.
- Further research could explore broader applications and comparative effectiveness.